Atlas Trials

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

Clinical trial NCT04957485 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04957485
Sponsor
SIGA Technologies
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Smallpox
Start date
2022-04-05
Primary completion
2027-01-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.